007570 — Ilyang Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Annual income statement for Ilyang Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS/A	ARS/A	ARS/A	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	343,329	242,511	247,773	266,669	268,861
Cost of Revenue
Gross Profit	181,709	104,750	108,310	116,493	111,475
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	311,175	227,031	233,549	266,750	257,858
Operating Profit	32,154	15,481	14,223	-80.8	11,003
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	28,393	22,063	23,846	-1,799	12,277
Provision for Income Taxes
Net Income After Taxes	21,545	14,752	19,806	-2,030	10,508
Minority Interest
Net Income Before Extraordinary Items
Net Income	10,880	14,032	19,385	-2,409	10,257
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	10,880	14,032	18,933	-2,365	10,013
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	673	761	1,045	463	557
Dividends per Share